Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication
Santseharay Ramírez, Carlota Fernandez-Antunez, Andrea Galli, et al.
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 7
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 382
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
Yuyong Zhou, Karen Anbro Gammeltoft, Line A. Ryberg, et al.
Science Advances (2022) Vol. 8, Iss. 51
Open Access | Times Cited: 165
In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2
Agnieszka M. Szemiel, Andres Merits, Richard Orton, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 9, pp. e1009929-e1009929
Open Access | Times Cited: 138
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 118
Accelerating antiviral drug discovery: lessons from COVID-19
Annette von Delft, Matthew D. Hall, Ann D. Kwong, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 585-603
Open Access | Times Cited: 94
Inferring effects of mutations on SARS-CoV-2 transmission from genomic surveillance data
Brian Lee, Ahmed Abdul Quadeer, Muhammad S. Sohail, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
In vitro efficacy of artemisinin-based treatments against SARS-CoV-2
Yuyong Zhou, Kerry Gilmore, Santseharay Ramírez, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 82
The roles of lipids in SARS-CoV-2 viral replication and the host immune response
Katherine N. Theken, Soon Yew Tang, Shaon Sengupta, et al.
Journal of Lipid Research (2021) Vol. 62, pp. 100129-100129
Open Access | Times Cited: 70
Replication and single-cycle delivery of SARS-CoV-2 replicons
Inna Ricardo-Lax, Joseph M. Luna, Tran Thi Nhu Thao, et al.
Science (2021) Vol. 374, Iss. 6571, pp. 1099-1106
Open Access | Times Cited: 69
Choosing a cellular model to study SARS-CoV-2
Gabriel Augusto Pires de Souza, Marion Le Bideau, Céline Boschi, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 42
Evolution of ACE2-independent SARS-CoV-2 infection and mouse adaption after passage in cells expressing human and mouse ACE2
Kexin Yan, Troy Dumenil, Tang Bing, et al.
Virus Evolution (2022) Vol. 8, Iss. 2
Open Access | Times Cited: 30
Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy
Markus Hoffmann, Anzhalika Sidarovich, Prerna Arora, et al.
mBio (2022) Vol. 13, Iss. 3
Open Access | Times Cited: 29
Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication
Ulrik Fahnøe, Long V. Pham, Carlota Fernandez-Antunez, et al.
Viruses (2022) Vol. 14, Iss. 2, pp. 172-172
Open Access | Times Cited: 28
Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform
Denisa Bojková, Philipp Reus, Leona Panosch, et al.
iScience (2023) Vol. 26, Iss. 2, pp. 105944-105944
Open Access | Times Cited: 16
Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination
Alexander P. Underwood, Christina Sølund, Carlota Fernandez-Antunez, et al.
EBioMedicine (2023) Vol. 89, pp. 104475-104475
Open Access | Times Cited: 16
Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2
Alexander P. Underwood, Christina Sølund, Kivin Jacobsen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection
Katharina Wørzner, S. Schmidt, Julie Zimmermann, et al.
EBioMedicine (2025) Vol. 113, pp. 105615-105615
Open Access
T cell receptor usage and epitope specificity amongst CD8+ and CD4+ SARS-CoV-2-specific T cells
Ulrik Fahnøe, Shan Feng, Alexander P. Underwood, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Artemisia absinthium- longevity modulator
С. В. Петров, Valery Lesnichy, Andrey Dolgan, et al.
Endocrinology&Metabolism International Journal (2025) Vol. 13, Iss. 1, pp. 12-16
Closed Access
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro
Karen Anbro Gammeltoft, Yuyong Zhou, Carlos R. Duarte Hernandez, et al.
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 9
Open Access | Times Cited: 36
Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1
Markus Hoffmann, Stefan Pöhlmann
Cell Research (2021) Vol. 32, Iss. 1, pp. 1-2
Open Access | Times Cited: 33
Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy
Dennis Christensen, Charlotta Polacek, Daniel J. Sheward, et al.
EBioMedicine (2022) Vol. 84, pp. 104248-104248
Open Access | Times Cited: 26
Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
Karen Anbro Gammeltoft, Yuyong Zhou, Line A. Ryberg, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1970-1970
Open Access | Times Cited: 12
TMEM106B-mediated SARS-CoV-2 infection allows for robust ACE2-independent infection in vitro but not in vivo
Kexin Yan, Troy Dumenil, Romal Stewart, et al.
Cell Reports (2024) Vol. 43, Iss. 11, pp. 114921-114921
Open Access | Times Cited: 4
SARS-CoV-2 mutations acquired during serial passage in human cell lines are consistent with several of those found in recent natural SARS-CoV-2 variants
Hoyin Chung, Ji Yeong Noh, Bon‐Sang Koo, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 1925-1934
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top